Study on the Effectiveness of AVTX-009 for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

2 1

What is this study about?

This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin. The study will evaluate a treatment called AVTX-009, which is a solution for injection developed by Avalo Therapeutics. The purpose of the study is to assess how effective and safe AVTX-009 is for patients with moderate to severe forms of this condition.

Participants in the study will receive either the AVTX-009 treatment or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure the results are unbiased. The treatment will be administered through subcutaneous injections, which means it is injected under the skin. The study will last for a period of 16 weeks, during which the participants’ response to the treatment will be closely monitored.

The main goal is to see if the treatment can reduce the number of painful lumps and improve the overall condition of the skin. Participants will be evaluated on their progress, and any side effects will be recorded to ensure the safety of the treatment. The study will also look at other factors, such as changes in skin pain and the presence of any antibodies against AVTX-009. This research aims to provide valuable information on a potential new treatment option for those suffering from Hidradenitis Suppurativa.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and a physical examination to ensure there are no signs of tuberculosis (TB).

A negative result from a QuantiFERON-TB Gold test or a tuberculin skin test is required, along with a negative chest radiograph.

2 baseline evaluation

A baseline evaluation is performed to document the current state of the condition, hidradenitis suppurativa (HS). This includes counting the number of abscesses and inflammatory nodules (AN) and assessing the severity of the condition.

3 treatment administration

Participants are randomly assigned to receive either the study drug, AVTX-009, or a placebo. The medication is administered as a subcutaneous injection, which means it is injected under the skin.

The frequency and dosage of the injections are determined by the study protocol and are administered over a specified period.

4 ongoing monitoring

Regular monitoring is conducted to track the progress of the treatment. This includes checking for any side effects, changes in vital signs, and conducting physical examinations.

Participants are required to maintain an electronic diary to record their symptoms and any changes they experience.

5 evaluation of treatment efficacy

The primary goal is to assess the effectiveness of AVTX-009 by measuring the reduction in abscess and inflammatory nodule count. A successful outcome is defined as achieving a 75% reduction in these counts by week 16, without an increase in abscess or draining fistula counts.

Secondary evaluations include measuring the incidence of adverse events and changes in the severity of the condition.

6 final assessment

At the end of the treatment period, a final assessment is conducted to evaluate the overall impact of the treatment. This includes a comprehensive review of all collected data and a final physical examination.

Who Can Join the Study?

The person must be at least 18 years old at the time they agree to join the study.
The person must be able to understand and sign a form agreeing to participate in the study, follow the study rules, read and understand study questions, and use an electronic diary.
The person must have had signs and symptoms of hidradenitis suppurativa (HS), a skin condition, for at least 6 months before the study starts, as determined by the study doctor.
The person’s HS must be moderate or severe, which means having at least 5 inflamed areas on the skin and these areas must be in at least 2 different body parts, with at least one part being more advanced (Hurley Stage 2 or 3).
The person must meet certain criteria for tuberculosis (TB) screening, which includes having no history of TB, not being treated for TB, showing no signs of TB, having a negative TB test, and a clear chest X-ray or CT scan.
Women who can have children and are sexually active, as well as female partners of men who are not sterile, must use a highly effective birth control method for 28 days before starting the study, during the study, and for 14 weeks after the last dose of the study drug.
Participants must agree not to donate eggs or sperm for assisted reproduction during the study and for 14 weeks after the last dose of the study drug.

Who Cannot Join the Study?

Patients who do not have moderate to severe hidradenitis suppurativa (HS) cannot participate. HS is a skin condition that causes small, painful lumps under the skin.
Patients who are not within the specified age range for the study cannot participate. The age range is typically defined in the study details.
Patients who are part of a vulnerable population, which means they might need special protection or care, cannot participate.
Patients who do not meet other specific health criteria set by the study cannot participate. These criteria are usually detailed in the study’s guidelines.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
IRCCS Humanitas Research Hospital	Rozzano	Italy
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz	Mainz	Germany
Technische Universitaet Dresden	Dresden	Germany
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Rome	Italy
Azienda Ospedaliera Universitaria Universita’ Degli Studi Della Campania Luigi Vanvitelli	Naples	Italy
Royalderm Agnieszka Nawrocka	Warsaw	Poland
Sanare spol. s r.o.	Svidnik	Slovakia

Other Sites

Site Name	City	Country
Centre Hospitalier Universitaire Rouen	Rouen	France
Azienda Ospedaliero Universitaria Di Modena	Modena	Italy
Hopital Beaujon	Clichy	France
Dkc Fokus-5 Lzip OOD	Sofia	Bulgaria
Crpyqcymld Pdurswwfdnj Lndoiadvvvyidfqueovkvwx Medykdkh sfxkd	Wroclaw	Poland
Fneeszmy nlweobytd Mfzow a Hmxlmzn	Prague	Czechia
Ulmsxlawijkpntvrervde Euqokoiz Axm	Erlangen	Germany
Fvblsnyobr Ieqdl Cb Gbfpqz Oswvhoeg Mzgkyhoo Pmxxtfineoh	Milan	Italy
Fzdmtjvr Nnuakpcdw Kvxbqvkrl Vgqomlrkf	Prague	Czechia
Ubkvrxxozknxlljue Pmcjyvhpweh Dnyie Marghl	Ancona	Italy
Urfecedukebqvlbopobae Mgjopffs Adg	Munster	Germany
Hoeiztl Phoqo D Adrctn	Antony	France
Codzle Hbdyhcxnikf Uybyksiewgunj Avalmq Pmpcibnq	Amiens	France
Izfozy Iflsqwni Fteyupynyewwh Ozpvzoqtbrd	Rome	Italy
Ufhcthyurocknaqpn Dstos Suyjl Dg Fsvytvm	Ferrara	Italy
Fmpouusb Nxkixyaqd Tejzxg	Trnava	Slovakia
Hmbpglgt Udtiqbgmebxtp Vbghqq Da Lzq Nkmkdd	Granada	Spain
Midquxh Cyrlei Mocmrebjjm Ptuxmy Oqy	Pleven	Bulgaria
Uaumozysgq Grazpro Hpthfpyt Acihlec	Athens	Greece
Azxjnfw Ogjigypehokgoftktxoolfnmy Puwsanlunwt Ge Rcftjowzkcbf Mrgrh Dz Cqsjfut	Catania	Italy
Gwthinv Hforpucc Ou Tzwdbazplddr Pbrqaxxdcjxw	Thessaloniki	Greece
Usooowolgpcazqgzt De Pzia	Pisa	Italy
Abvnnpb Sqydvxv Hjtdfcpw Of Vnrinagm Axn Dfbcxuqhrxfmvu Dldrweee	Athens	Greece
Pocwmjxkn Ienmamrb Mtbtjkyw Mjiwhnakcezi Suewz Wcpegjudxfre I Auolqnyuniyxg	Warsaw	Poland
Gppzbc Uwrsyonsqc Fzoppjlnj	Frankfurt	Germany
Sdt Jquonqdrcrzrqy	Bochum	Germany
Hozalvfh Eukgpyc Huunfrd	Lyon	France
Hyjbfjjb Sjvrr Mzwus Dyllh Mlereukrquuq	Perugia	Italy
Wetxpkoya I Bburlkin A Stlpmkzfdybt srmz	Wroclaw	Poland
Ulvyx &ykuxlc Pvrut Dfi Shjioc Kzjtxvlyf Ac	Stara Zagora	Bulgaria
Lmtybet Ezszxcq Sts z ohel	Ozarowice	Poland
Nimikjqjzfep Zispds Oirozq Zocztecmjt Slsqbfiuktsnqci Ouuqqam Djkebqaypqddbdi &npzxqfepgjpdtpytquf	Bialystok	Poland

Trial status

Country	Status	Recruitment Start
Bulgaria	Not recruiting	12.02.2025
Czechia	Not recruiting	12.02.2025
France	Not recruiting	12.02.2025
Germany	Not recruiting	12.02.2025
Greece	Not recruiting	12.02.2025
Italy	Not recruiting	12.02.2025
Poland	Not recruiting	12.02.2025
Slovakia	Not recruiting	12.02.2025
Spain	Not recruiting	12.02.2025

Trial locations

Investigated Drugs:

AVTX-009

AVTX-009 is an investigational medication being studied for its potential to treat moderate to severe hidradenitis suppurativa, a chronic skin condition characterized by painful lumps under the skin. The trial aims to assess how effective and safe this medication is for patients suffering from this condition.

Investigated Diseases:

Hidradenitis

Hidradenitis Suppurativa – Hidradenitis suppurativa is a chronic skin condition characterized by the formation of painful lumps under the skin, typically in areas where skin rubs together, such as the armpits, groin, and under the breasts. These lumps can become inflamed and may rupture, leading to the formation of abscesses and tunnels under the skin. Over time, the condition can cause scarring and the development of sinus tracts, which are channels that connect the lumps under the skin. The disease often progresses with periods of flare-ups and remission, where symptoms may temporarily improve. The exact cause of hidradenitis suppurativa is not fully understood, but it is believed to involve a combination of genetic, hormonal, and environmental factors.

Trial ID:

2024-514562-40-00

Protocol code:

AVTX-009-HS-201

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effectiveness of AVTX-009 for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?